Tags: treatment + drug company.with.MS

Sort by: Date / Title / URL

1. ScienceDaily: Genes That Affect Responses Of Multiple Sclerosis Patients To Copaxone Identified
   In the past few years, it has been shown that many drugs are not equally effective for every patient, and this variability is due, at least in part, to genetic differences.
   11-10-2007 to copaxone, drug company, drugs, genetics, ms, multiple sclerosis, treatment by admin
2. Merck KGaA's Rebif, Teva's Copaxone similar-study | Health | Reuters
   The number of events (relapses) was insufficient to establish a statistically significant difference between the two products, despite a trend advantage for Rebif
   11-10-2007 to copaxone, drug company, drugs, interferon, rebif, study, treatment by admin
3. Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
   The BENEFIT study (BEtaseron in Newly Emerging multiple sclerosis For Initial Treatment), sponsored by Bayer HealthCare, compared Betaseron treatment initiated after a first clinical event with delayed treatment.
   03-08-2007 to betaseron, drug company, drugs, interferon, ms, multiple sclerosis, newly diagnosed, study, treatment by admin
4. Biogen, PDL drug passes clinical trial
   Patients given daclizumab every two weeks had a significantly reduced lesions at week 24 compared with those in the placebo group.
   13-03-2007 to clinical trial, daclizumab, drug company, drugs, interferon, multiple sclerosis, relapsing remitting, treatment by admin
5. Accentia Biopharmaceuticals Acquires Worldwide Exclusive License to Revimmune for All Autoimmune Diseases - PipelineReview.com | Business Intelligence Center
   In clinical studies for the lead indication of multiple sclerosis (MS), Revimmune improves function in most patients and stops progression in over 90% of cases refractory to standard therapies;
   05-03-2007 to drug company, drugs, immune, multiple sclerosis, revimmune, treatment by admin
6. BioMS Medical initiates follow-on open-label MAESTRO-02 Multiple Sclerosis trial of MBP8298
   BioMS Medical Corp (TSX: MS), a leading developer of products for the treatment of multiple sclerosis (MS), today announced that it has initiated MAESTRO-02, the open-label follow-on portion to its MAESTRO-01 pivotal phase II/III clinical trial of MBP8298
   05-03-2007 to drug company, drugs, mbp8298, multiple sclerosis, spms, treatment by admin
7. Peptimmune Online - CO - 14
   The new peptides have been found to be more effective than Copaxone® in in-vitro and in-vivo assays, as well as in animal disease models of MS.
   17-02-2007 to copaxone, drug company, drugs, eae, multiple sclerosis, research, treatment by admin
8. TERMS
   The TERMS (Tovaxin for Early Relapsing Multiple Sclerosis) study is testing Tovaxin, an autologous T-Cell vaccination in patients with Clinically Isolated Syndrome or Relapsing-Remitting Multiple Sclerosis
   15-02-2007 to clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, tovaxin, treatment by admin
9. Merck Serono Has Initiated The Onward Study To Evaluate Oral Cladribine As Add-On Treatment For Multiple Sclerosis - PipelineReview.com | Business Intelligence Center
   Merck Serono announced today that it has begun the ONWARD (Oral Cladribine Added ON To Rebif New Formulation in Patients With Active Relapsing Disease) Phase II study.
   07-02-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, rebif, research, treatment by admin
10. Merck Serono Completes Patient Enrollment in CLARITY Phase III Pivotal Clinical Trial of Oral Cladribine
    Merck Serono announced today that patient enrollment has been completed in the CLARITY (CLAdRIbine Tablets Treating MS OrallY) study, a Phase III pivotal clinical trial evaluating the efficacy and safety
    17-01-2007 to cladribine, clinical trial, drug company, drugs, multiple sclerosis, relapsing remitting, research, rrms, treatment by admin
11. AVONEX, the Most Prescribed Multiple Sclerosis Therapy Worldwide, Launched in Japan. Genetic Engineering News - Biotechnology from Bench to Business
    In July 2006, the Japanese Ministry of Health, Labour and Welfare approved AVONEX for the prevention of MS relapse. AVONEX is the first new MS treatment available in Japan in six years
    11-11-2006 to avonex, drug company, drugs, treatment by admin
12. MultiCell Technologies CEO to Present Key Research Data at New York Academy of Sciences' Animal Models Conference
    MultiCell is focused on the development of MCT-125 and MCT-275. MCT-125 is a first-in-class drug for treatment of chronic fatigue in patients with multiple sclerosis.
    08-11-2006 to drug company, drugs, fatigue, multiple sclerosis, symptoms, treatment by admin
13. Avonex Improves Patient Convenience
    AVONEX(R) (Interferon beta-1a), the most prescribed multiple sclerosis (MS) therapy worldwide, may now be stored at room temperature (up to 77 degrees F or 25 degrees C) in its prefilled formulation for a period up to 7 days.
    21-10-2006 to avonex, drug company, drugs, interferon, multiple sclerosis, relapsing remitting, rrms, treatment by admin
14. Immune Response launches mid stage trial of new MS treatment - Pharmaceutical Business Review
    The Immune Response Corporation has launched a phase II trial to assess the potential of NeuroVax to treat patients with multiple sclerosis.
    13-10-2006 to clinical trial, drug company, drugs, multiple sclerosis, neurovax, treatment, us by admin
15. TYSABRI.com
    TYSABRI® is indicated as monotherapy for the treatment of patients with relapsing forms of multiple sclerosis to delay the accumulation of physical disability and reduce the frequency of clinical exacerbations.
    07-10-2006 to drug company, drugs, multiple sclerosis, relapsing remitting, rrms, treatment, tysabri by admin

First / Previous / Next / Last / Page 1 of 3